Hill­house Cap­i­tal en­dors­es Chi­na-based Hai­He Bio­phar­ma's can­cer pipeline in $146M round

Count Hai­He Bio­phar­ma in the new gen­er­a­tion of Chi­nese biotechs an­swer­ing the clar­i­on call for home­grown in­no­va­tion.

The Shang­hai-based drug­mak­er is emerg­ing from rel­a­tive ob­scu­ri­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER